Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy

Oct 09 2018

• By Mandy Jackson

3-D Rendering Red Blood Cells

Related Content

Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern

Nov 17 2017

Hemophilia: How To Please Payers And Secure Market Share

Mar 03 2017

Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests

Jul 16 2018

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

Oct 06 2018

UniQure Hemophilia B Gene Therapy Changes Ignite A Race To Market

Oct 19 2017

Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity

Oct 04 2018

BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications

May 23 2018

Related Companies

Spark Therapeutics, Inc.

Pfizer Inc.

BioMarin Pharmaceutical Inc.

Sangamo Therapeutics, Inc.

uniQure N.V.

Roche Holding AG

Additional Topics

Regenerative Medicine Reimbursement Market Access Rare Diseases Commercial Blood & Coagulation Disorders BioPharmaceutical

More from Cell Therapies

More from Advanced Therapies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window